Relmada Therapeutics, Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of approximately $10.1 million for the third quarter, a decrease from a loss of $21.7 million in the same period last year. For the nine months ended September 30, 2025, the net loss was approximately $37.5 million, down from $61.3 million in the prior year. The loss per share for the quarter was $0.30, compared to $0.72 in the previous year, indicating a reduction in losses as the company continues to streamline its operations.
Total operating expenses for the third quarter were approximately $10.3 million, a significant decrease from $23 million in the same quarter of 2024. This reduction was primarily driven by lower research and development expenses, which fell to $4 million from $11.1 million, largely due to the winding down of the REL-1017 studies. General and administrative expenses also decreased to $6.3 million from $11.9 million, reflecting a reduction in stock-based compensation and consulting services. The company’s total assets decreased to $14.9 million from $45.8 million at the end of 2024, primarily due to a reduction in cash and short-term investments.
Strategically, Relmada has made significant changes to its development pipeline. The company terminated its esmethadone program in July 2025 and the psilocybin program in May 2025, focusing instead on its lead product, NDV-01, which is currently in a Phase 2 clinical trial for non-muscle invasive bladder cancer (NMIBC). Additionally, Relmada acquired Sepranolone, a neurosteroid in development for various conditions, including Prader-Willi Syndrome and Tourette Syndrome. The company expects to initiate Phase III trials for NDV-01 in the first half of 2026.
Operationally, Relmada's employee headcount has been adjusted in line with its strategic focus, although specific numbers were not disclosed. The company has also regained compliance with Nasdaq listing requirements after its stock price met the minimum bid price for ten consecutive days in September 2025. As of September 30, 2025, Relmada had approximately $1.4 million in cash and cash equivalents, down from $3.9 million at the end of 2024, and $12.5 million in short-term investments, a decrease from $41 million.
Looking ahead, Relmada anticipates key milestones in the coming year, including the initiation of Phase IIb studies for Sepranolone and Phase III trials for NDV-01. The company recently completed an underwritten offering that raised approximately $94 million, which it believes will provide sufficient liquidity to fund operations for at least the next 12 months. Management remains focused on leveraging its drug development expertise to enhance shareholder value through its revised strategic direction.
About RELMADA THERAPEUTICS, INC.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing novel drugs for neurological, psychiatric, and cancer-related conditions. Its pipeline includes candidates targeting depression, Tourette Syndrome, bladder cancer, and neurosteroid-related disorders. The company leverages extensive intellectual property, strategic licensing, and acquisitions to address high unmet medical needs, aiming for long-term growth through innovative, differentiated therapies in large markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.